FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to obstetrics, pathological physiology, and can be used for prediction of placental insufficiency in the third trimester of pregnancy in women suffering moderate COVID-19 in the first trimester. In females, blood serum is analysed for the concentration of sTNF-R1 in pg/ml and sVEGF-R1 in pg/ml using the enzyme immunoassay method. Development of placental insufficiency is predicted using a prognostic index: PI = 7.668 – 0.006 × sTNF-R1 + 1.74 × sVEGF-R1, where PI is a discriminant function, the boundary value of which is 1.132. If PI is equal to or greater than the limit value, developing placental insufficiency in the third trimester of pregnancy in women with moderate course of COVID-19 in the first trimester is predicted. If PI is less than the limit value, no risk of developing placental insufficiency in the third trimester of pregnancy in women with moderate course of COVID-19 in the first trimester is predicted.
EFFECT: method provides the possibility of increasing the accuracy of prediction of placental insufficiency in the third trimester of pregnancy in women with moderate course of COVID-19 in the first trimester, by determining the concentration of sTNF-R1 and sVEGF-R1 in blood serum by enzyme immunoassay and calculation by the declared discriminant function.
1 cl, 2 ex
